Table 4 Results of the published instruments assessing causal relationship between medication exposure and adverse events when applied to patients in this case series
Medication(s) | Naranjo score | Kramer score | WHO score |
|---|---|---|---|
Biologics | |||
Adalimumab | Possible | Possible | Possible |
Certolizumab pegol | No use reported in any case report | ||
Infliximab | Possible | Possible | Possible |
Natalizumab | Possible | Possible | Possible |
Ustekinumab | Possible | Possible | Possible |
Anti-metabolites | |||
6-mercaptopurine | Possible | Possible | Possible |
Azathioprine | Possible | Possible | Possible |
Aminosalicylates | |||
Balsalazide | Possible | Unlikely | Possible |
Mesalamine | Possible | Unlikely | Possible |
Sulfasalazine | Possible | Unlikely | Possible |
Corticosteroids | |||
Budesonide | Possible | Unlikely | Possible |
Hydrocortisone | Possible | Unlikely | Possible |
Prednisone | Possible | Unlikely | Possible |
Prednisolone | Possible | Unlikely | Possible |
Corticosteroid unspecified | Possible | Unlikely | Possible |
Other medications | |||
Cyclosporine | Possible | Possible | Possible |
Metronidazole | Possible | Unlikely | Possible |
Nitrofurantoin | Possible | Unlikely | Possible |
Piperacillin/tazobactam | Possible | Unlikely | Possible |
Doxycycline | Possible | Unlikely | Possible |
Ciprofloxacin | Possible | Unlikely | Possible |